Onconova ONTX - Nasdaq - Verdoppelungschance

Gestern nach Börsenschluss folgende Kaufempfehlung:
Gesamt-Rating: 1 - strong buy
Zacks: Rating 2 - seit gestern - buy


Onconova Therapeutics, Inc. (NASDAQ:ONTX) shares have been an average broker rating (ABR) of 1 at Zacks Research. This is based on a simplified scale taking into account the recommendations posted by 2 research firms covering the stock, tracked by Zacks. A stock with a low ABR (1 or 2) means that is either rated a Buy or Strong Buy on a consensus basis. A stock with a higher ABR (3-5) typically means analysts recommending to Hold or Sell. Three months ago the stock’s ABR was at 1, which gives a glance at which direction the sentiment is headed.

The research analysts covering the equity also have issued future price target predictions for the company. On a consensus basis, Wall Street sees the stock going to $6 within the year. The most aggressive analyst sees the stock reaching $6 which the most conservative has their target at $6.

Earnings in Spotlight

Sell-side analysts on Wall Street are estimating that Onconova Therapeutics, Inc. (NASDAQ:ONTX) will report earnings per share of $-0.28 for the current quarter which will end on 2015-09-30. This number is based on the mean numbers from the analysts tracked by Zacks

Investors and potential shareholders will be closely watching when Onconova Therapeutics, Inc. issues their next quarterly earnings report on or around 2015-11-12. They will be paying particular attention to how the company’s actual earnings matches up against Wall Street expectations. Most recently, the company posted an earnings surprise factor of 26.79%, or a difference of $0.15 per share from what analysts were anticipating.